Perspective Therapeutics (CATX) Asset Utilization Ratio (2011 - 2023)
Perspective Therapeutics' (CATX) quarterly Asset Utilization Ratio came in at 0.01 in Q4 2023, down 88.22% quarter-over-quarter from 0.12 in Q3 2023.
Analysis
Perspective Therapeutics (CATX) Asset Utilization Ratio (2011 - 2023) Analysis & Trends
Perspective Therapeutics has disclosed Asset Utilization Ratio across 12 years of filings, most recently posting 0.01 for Q4 2023.
- In Q4 2023, Asset Utilization Ratio changed N/A year-over-year to 0.01; the TTM figure through Dec 2023 stood at 0.01 (changed N/A YoY), while the FY2023 annual figure was 0.02, changed N/A from the prior year.
- Asset Utilization Ratio came in at 0.01 for Q4 2023 at Perspective Therapeutics, down from 0.12 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 1.17 in Q3 2020 to a low of 0.01 in Q4 2023.
- Average Asset Utilization Ratio over 5 years is 0.47, with a median of 0.22 recorded in 2021.
- Year-over-year, Asset Utilization Ratio tumbled 87.38% in 2021 and jumped 95.65% in 2022.
- Over 5 years, Asset Utilization Ratio stood at 0.88 in 2019, then fell by 4.21% to 0.84 in 2020, then tumbled by 81.31% to 0.16 in 2021, then surged by 83.03% to 0.29 in 2022, then tumbled by 95.22% to 0.01 in 2023.
- Per Business Quant data, the three most recent Asset Utilization Ratio figures were 0.01 in Q4 2023, 0.12 in Q3 2023, and 0.13 in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 0.40 |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 0.58 |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 0.47 |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 0.38 |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 0.20 |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 0.90 |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 0.33 |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 0.00 |
| 10 | Perspective Therapeutics | 361.95 Mn | 361.95 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 0.01 |
| Sep 30, 2023 | 0.12 |
| Jun 30, 2023 | 0.13 |
| Mar 31, 2023 | 0.19 |
| Sep 30, 2022 | 0.29 |
| Jun 30, 2022 | 0.21 |
| Mar 31, 2022 | 0.16 |
| Dec 31, 2021 | 0.16 |
| Sep 30, 2021 | 0.15 |
| Jun 30, 2021 | 0.14 |
| Mar 31, 2021 | 0.22 |
| Dec 31, 2020 | 0.84 |
| Sep 30, 2020 | 1.17 |
| Jun 30, 2020 | 1.10 |
| Mar 31, 2020 | 1.04 |
| Dec 31, 2019 | 0.88 |
| Sep 30, 2019 | 0.83 |
| Jun 30, 2019 | 0.73 |
| Mar 31, 2019 | 0.62 |
| Dec 31, 2018 | 0.53 |